Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega

Alkermes plc ALKS reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56.

The company reported sales of $617.40 million, 124% higher than the $276.22 million reported a year, beating the consensus estimate of $585.02 million.

Q2 sales reflect the strong performance of the proprietary product portfolio and the reinstatement of long-acting Invega product royalties.

Net sales of proprietary products increased by approximately 21% to $231.5 million.

Total revenues included $248.4 million of back royalties and associated interest related to the successful outcome of the company's arbitration with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson JNJ.

Alkermes increased its FY23 outlook by $425 million to reflect the company's final award from an arbitration proceeding.

The company revised forecasts for FY23 revenue to $1.55 billion - $1.68 billion, from prior guidance of $1.13 billion - $1.25 billion versus the consensus of $1.32 billion.

The company sees adjusted EPS of $1.34 – $1.57 compared to $0.00 – $0.23 expected earlier and the consensus of $0.42.

-In June 2023, Alkermes appointed Caroline Loew, the chief executive officer designate of Mural Oncology plc, the new independent public company to be established upon the planned separation of Alkermes' oncology business. 

Dr. Loew joined Alkermes in June as a strategic advisor and will transition to Mural Oncology's CEO upon separation completion, expected in the second half of 2023.

Price Action: ALKS shares are down 4.15% at $29.56 on the last check Wednesday.